Ongoing Assessments & Recent Research.
Easy access to our work
Metachromatic Leukodystrophy
Sep 2023Paroxysmal Nocturnal Hemoglobinuria
Feb 2024Pulmonary Arterial Hypertension
Dec 2023Schizophrenia
Feb 2024September Milestones
Every few years, we revisit ICER’s Value Assessment Framework, which is the backbone of ICER’s rigorous, transparent evidence reports that, as a basis for broader stakeholder and public engagement, will help the United States evolve toward a health care system that provides sustainable access to high-value care for all patients. Read the 2023 Value Assessment Framework.
Register here for the Sept 28th webinar explaining all of the changes.
In an upcoming webinar, President Steven Pearson, MD, MSc, and President-Elect Sarah Emond, MPP, will summarize the philosophy behind ICER’s approach to value assessment, as well as several key updates that will be implemented in the near term.
Register here for the Sept 28th webinar explaining all of the changes.
ICER recently posted an Evidence Report assessing the comparative clinical effectiveness and value of atidarsagene autotemcel (“arsa-cel”, Orchard Therapeutics) for metachromatic leukodystrophy (MLD).
This Evidence Report will the basis for our Sept 29th virtual public meeting, where an independent appraisal committee will review the evidence, hear further testimony from stakeholders, and deliberate on the treatment’s comparative clinical effectiveness, other potential benefits, and long-term value for money. Register here.
Featured News & Insights.
Learn about our latest work.
ICER Releases Draft Evidence Report on Treatment for Pulmonary Arterial Hypertension
Public comment period now open until October 23, 2023; Requests to make oral comment during public meeting also being accepted
09/25/2023ICER Finalizes 2023 Updates to Value Assessment Framework
Updates to methods and public meeting procedures reflect experience with previous framework, benchmarking with other HTA groups, and input from external organizations and individuals across the US health system.
09/25/2023ICER Publishes Evidence Report on Gene Therapy for Metachromatic Leukodystrophy
Currently available evidence provides greater certainty of substantial net health benefit in pre-symptomatic MLD; evidence also suggests that individuals with early symptomatic disease benefit from treatment.
09/14/2023Our Origin Story.
ICER President Dr. Steve Pearson explains why he founded an organization to advance the use of evidence to improve health care affordability and access for all patients and their families.
The ICER Impact.
New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $500 million
Engaged with over 400 patient groups and patient reps
In a landmark international program, HTA agencies around the world can now access ICER’s customizable COVID-19 Cost-Effectiveness Model
Latest
Developments.
In 2021, we celebrated our 15th anniversary! Learn more.
In early 2023, ICER collaborated with NICE and CADTH on HTA methods. Learn more.
Listen to our podcast, “A Prescription for Fair Pricing“. Subscribe now on Apple, Google, or Spotify.
Current
Policy Papers.
Easy access to our latest policy papers
Barriers to Fair Access
Second annual scorecard of barriers to fair access criteria; during ICER’s assessment, five payers revised policies for 11 drugs in ways that bring coverage into concordance with fair access criteria, demonstrating that assessment and greater transparency may lead to positive change
Unsupported Price Increases
Seven out of 10 high-expenditure drugs had substantial 2021 net price increases that were not supported by new clinical evidence; these increases accounted for $805 million in additional costs over one year.
Additionally, three Medicare Part B drugs with high list price increases in 2020 lacked adequate supporting new evidence, directly raising annual out-of-pocket expenses for Medicare patients by up to $3,200 per year.
Evaluating and Advancing Health Technology Assessment Methods that Support Health Equity
ICER received a new grant from The Commonwealth Fund to evaluate procedural and methodological changes that could further support health equity goals in health technology assessment (HTA). The findings from this effort will guide ICER’s update to its value assessment framework and inform the work of other HTA groups worldwide.